We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Method Identifies Anthrax Bacteria Faster Than Current Approaches

By LabMedica International staff writers
Posted on 06 Mar 2014
A new method has been developed for rapid diagnostic detection and antibiotic susceptibility determination of the pathogenic Bacillus anthracis using a bioluminescent reporter phage.

Although anthrax is a treatable disease, positive patient prognosis is dependent on rapid diagnosis and therapy. More...
A team at the University of Missouri (MU; Columbia, MO, USA) assessed a bioluminescent reporter phage, developed by David Schofield at Guild BioSciences (Charleston, SC, USA), for its value as a clinical diagnostic tool for Bacillus anthracis. The reporter phage based method, published in the Journal of Microbiological Methods (November 2013), detects live B. anthracis strains by transducing a bioluminescent phenotype. It was found to rule out false positives – displaying species specificity by its inability, or significantly reduced ability, to detect members of the closely related Bacillus cereus group and other common bacterial pathogens.

The method detects low levels of B. anthracis, at clinically relevant bacterial concentrations, within 5 hours. “Normally to identify whether an organism is present, you have to extract the material, culture it, and then pick colonies to examine that might turn out to be anthrax bacteria,” said Prof. George Stewart, PhD, medical bacteriologist. “Then you conduct chemical testing which takes some time—a minimum of 24 to 48 hours. Using this newly-identified method, we can reduce that time to about 5 hours.” The method also provides antibiotic susceptibility information that mirrors the CLSI method, except that data are obtained at least 5-fold faster.

In addition to saving lives, the new method could also save on high clean up and decontamination costs of bioterrorism attacks. These costs for the post-9/11 2001 anthrax letters attack totaled USD 3.2 million, according to a 2012 report. “In the years since the post-9/11 postal attacks, we haven’t had any bona fide anthrax attacks,” said Prof. Stewart; “That doesn’t mean that it’s not going to happen, we just have to be prepared.” Current methods take 1–3 days to produce definitive results for anthrax. The new detection method would potentially alert of a negative result 5 hours into clean-up efforts instead of 1–3 days into expensive decontamination.

Related Links:
University of Missouri at Columbia
Guild Biosciences


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Automated Urinalysis Solution
UN-9000
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.